Sec Form 13G Filing - PURA VIDA INVESTMENTS LLC filing for Oncocyte Corp (OCX) - 2024-11-14

Insider filing report for Changes in Beneficial Ownership

  • Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
  • Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED
PURSUANT TO RULE 13d-2(b)

(AMENDMENT NO. 6)*

Oncocyte Corp
(Name of Issuer)

Common Stock, No. Par Value
(Title of Class of Securities)

68235C107
(CUSIP Number)

November 14, 2024
(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule
 is filed:

       [ X ] Rule 13d-1(b)
       [     ] Rule 13d-1(c)
       [     ] Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's
 initial filing on this form with respect to the subject class of securities,
and for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
 the Act but shall be subject to all other provisions of the Act (however, see
the Notes).


CUSIP No. 68235C107

13G

Page 1 of 8 Pages
1.
NAMES OF REPORTING PERSONS OR
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

Pura Vida Investments, LLC

2.
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)

(a) [    ]
(b) [ x ]
3.
SEC USE ONLY


4.
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
5.
SOLE VOTING POWER

 0

6.
SHARED VOTING POWER

616,587*

7.
SOLE DISPOSITIVE POWER

 0

8.
SHARED DISPOSITIVE POWER

616,587*
9.
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

616,587*

10.
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(see instructions) [  ]


11.
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 4.57%**

12.
TYPE OF REPORTING PERSON (see instructions)

 IA







CUSIP No. 68235C107

13G

Page 2 of 8 Pages
1.
NAMES OF REPORTING PERSONS OR
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

Efrem Kamen

2.
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)

(a) [    ]
(b) [ x ]
3.
SEC USE ONLY


4.
CITIZENSHIP OR PLACE OF ORGANIZATION
 USA

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
5.
SOLE VOTING POWER

 0

6.
SHARED VOTING POWER

616,587*

7.
SOLE DISPOSITIVE POWER

 0

8.
SHARED DISPOSITIVE POWER

 616,587*
9.
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

616,587*

10.
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(see instructions) [  ]


11.
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

4.57%**

12.
TYPE OF REPORTING PERSON (see instructions)

 IN, HC











CUSIP No. 68235C107

13G

Page 4 of 8 Pages

Item 1.

(a)
Name of Issuer

Oncocyte Corp




(b)
Address of Issuers Principal Executive Offices

15 Cushing, Irvine, CA, 92618
Item 2.

(a)
Name of Person Filing

Pura Vida Investments, LLC
Efrem Kamen
(collectively, the "Reporting Persons").




(b)
The address of the principal place of the Reporting Persons is located at:

Pura Vida Investments, LLC
545 West 25th Street, 19th Floor
New York, NY, 10001




(c)
 For citizenship of the Reporting Persons, see Item 4 of the cover sheet for
each Reporting Persons.





(d)
 Title of Class of Securities

Common Stock, No Par Value




(e)
CUSIP Number

68235C107
Item 3. If this statement is filed pursuant to Rules 13d-1(b) or 240.13d-2(b)
or (c), check whether the person filing is a:


(a)
[  ]
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).





(b)
[  ]
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).





(c)
[  ]
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).



(d)
[  ]
Investment company registered under section 8 of the Investment Company Act of
 1940 (15 U.S.C. 80a-8).



(e)
[x]
An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);





(f)
[  ]
An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)
(ii)(F);





(g)
[  ]
A parent holding company or control person in accordance with Rule 13d-1(b)(1)
(ii)(G);







(h)
[  ]
A savings associations as defined in Section 3(b) of the Federal Deposit
Insurance Act (12 U.S.C. 1813);






(i)
[  ]
A church plan that is excluded from the definition of an investment company
under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);





(j)
[  ]
Group, in accordance with Rule 13d-1(b)(1)(ii)(J).
CUSIP No. 68235C107

13G

Page 6 of 8 Pages
Item 4. Ownership.

(a) Amount beneficially owned:

Pura Vida Investments LLC 616,587* shares
Efrem Kamen 616,587* shares

(b) Percent of class:

Pura Vida Investments LLC 4.57%**
Efrem Kamen 4.57%**

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote: 0

(ii) Shared power to vote or to direct the vote:

Pura Vida Investments 616,587* shares
Efrem Kamen 616,587* shares

(iii) Sole power to dispose or to direct the disposition of: 0

(iv) Shared power to dispose or to direct the disposition of:

Pura Vida Investments, LLC 616,587* shares
Efrem Kamen 616,587* shares

* Shares reported herein are owned by Pura Vida Master Fund, Ltd. (the "Pura
Vida Master Fund"), Pura Vida X Fund LP (the "Pura Vida X Fund) and certain
separately managed accounts (the "Managed Accounts," collectively the "Client
 Accounts"). Pura Vida Investments, LLC ("PVI") serves as the investment
manager to the Client Accounts. Efrem Kamen serves as the Managing Member of
 PVI.  By virtue of these relationships, the Reporting Persons may be deemed
to have shared voting and dispositive power with respect to the shares owned
directly by the Client Accounts. This report shall not be deemed an admission
that the Reporting Persons are beneficial owners of the shares for purposes of
Section 13 of the Securities Exchange Act of 1934, as amended, or for any other
 purpose. Each of the Reporting Persons disclaims beneficial ownership of the
Shares reported herein except to the extent of the Reporting Persons pecuniary
interest therein, if any.  As of the date of this filing, shares reported
herein for the Reporting Persons include (1) 495,345 shares of Common Stock of
 the Issuer outstanding and (2) warrants to acquire up to 121,242 shares of
Common Stock of the Issuer.



CUSIP No. 68235C107

13G

Page 6 of 8 Pages
**The percentages herein are calculated based upon (1) 13,368,387 shares of
Common Stock of the Issuer outstanding per the Issuers Form 10-Q filed with
the Securities and Exchange Commission on August 8, 2024 and (2) 121,242 shares
 of Common Stock of the Issuer issuable upon exercise of warrants owned by the
Reporting Persons, which have been added to the total shares of Common Stock of
 the Issuer outstanding pursuant to Rule 12d-3(d)(3) under the Act.

Item 5. Ownership of Five Percent or Less of a Class.

N/A

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

N/A

Item 7. Identification and Classification of the Subsidiary Which Acquired the
Security Being Reported on By the Parent Holding Company.

N/A

Item 8. Identification and Classification of Members of the Group.

N/A

Item 9. Notice of Dissolution of Group.

N/A

Item 10. Certification.























CUSIP No. 68235C107

13G

Page 7 of 8 Pages


          By signing below I certify that, to the best of my knowledge and
belief, the securities referred to above were not acquired and are not held for
 the purpose of or with the effect of changing or influencing the control of
the issuer of the securities and were not acquired and are not held in
connection with or as a participant in any transaction having that purpose or
effect.

Exhibits.

Exhibit A Joint Filing Agreement.


SIGNATURE


After reasonable inquiry and to the best of my knowledge and belief, I certify
 that the information set forth in this statement is true, complete and
correct.

Dated: November 14, 2024


Pura Vida Investments, LLC

By: /s/ Efrem Kamen, Managing Member



























CUSIP No. 68235C107

13G

Page 8 of 8 Pages
EXHIBIT A
AGREEMENT REGARDING JOINT FILING
OF STATEMENT ON SCHEDULE 13D OR 13G

The undersigned hereby consent and agree to file a joint statement on Schedule
 13G under the Securities Exchange Act of 1934, as amended, with respect to the
 Pura Vida Investments, LLC. beneficially owned by them, together with any or
all amendments thereto, when and if appropriate. The parties hereto further
consent this Statement pursuant to Rule 13d-1(k)(1)(iii) as an exhibit to
Schedule 13G, thereby incorporating the same into such Schedule 13G.

Dated: November 14, 2024

Pura Vida Investments, LLC

By: /s/ Efrem Kamen, Managing Member